Coldrif Cough Syrup, a product once widely used by many families, has tragically become the focal point of a major public health crisis across several states. Since early September, a devastating toll of at least 14 child deaths has been reported in regions including Chhindwara, Madhya Pradesh, and Rajasthan. These young lives were lost due to suspected kidney failure, and a critical common factor in these heartbreaking cases has been identified: Coldrif cough syrup.
Official investigations conducted by state authorities on samples of Coldrif cough syrup, manufactured by Sresan Pharma in the southern state of Tamil Nadu, revealed a shocking discovery. The medicine was found to contain an alarming 48.6% diethylene glycol (DEG), a concentration that far surpasses safe and permissible limits. Diethylene glycol is not meant for medicinal consumption; it is a highly toxic substance commonly found in industrial solvents. Even in minimal quantities, ingesting DEG can be fatal, posing severe risks to human health.
In light of these critical findings and the tragic loss of life, numerous states have swiftly moved to implement a ban on the sale and distribution of Coldrif cough syrup to prevent further harm. This widespread action underscores the gravity of the situation and the immediate danger posed by the contaminated medicine. Public health officials are urging caution and awareness regarding pharmaceutical products.